Research On ESG Information Disclosure Of Lizhu Pharmaceutical

In recent years,climate change and environmental issues have become increasingly prominent,and China has put forward the goal of "double carbon" and advocated enterprises to develop a green economy.ESG information disclosure is the core of the whole ESG system,and the market demand for ESG information disclosure is also increasing day by day.After the outbreak of the new crown epidemic,the fulfillment of ESG responsibilities in the pharmaceutical industry has attracted much attention,and ESG reports,as an important vehicle to convey non-financial information of enterprises,are of great significance to improve the quality of ESG information disclosure.However,there is still a lack of relevant systematic research,and there are problems such as low disclosure quantity and low disclosure level.Based on this problem,this paper takes "A+H" listed Lizhu Pharmaceutical as a case study to analyze its disclosure quality.Thus,this paper firstly reviews the literature related to ESG and its information disclosure and sorts out ESG-related concepts;secondly,analyzes the overall situation of ESG information disclosure in the pharmaceutical industry by collating the data of sample listed pharmaceutical companies.Then,we select the pharmaceutical company Lizhu Pharmaceutical,which has continuously disclosed six ESG reports,as a case company,and analyze the content of its ESG reports for the past six years in detail;again,we use the index method to construct an information disclosure evaluation system that meets the characteristics of the pharmaceutical industry,and analyze Lizhu Pharmaceutical’s ESG reports in vertical and horizontal comparisons respectively;finally,through specific analysis,this paper finds that Lizhu Pharmaceutical’s ESG reports still have Finally,through specific analysis,this paper finds that the ESG report of Lizhu Medicine has problems such as incomplete information disclosure,lack of quantitative indicators,low value of some information,lack of industry characteristic indicators,and insufficient report authenticity.In view of the problems of Lizhu Pharma’s ESG report,and based on the current situation of disclosure in the pharmaceutical industry,relevant suggestions are put forward.At the corporate level,Lizhu Pharma needs to deepen the disclosure of qualitative and quantitative ESG contents,improve the ESG awareness of all employees and pay attention to the feedback of ESG report readers;at the social level,it needs to play the role of media publicity and strengthen the construction of ESG talent team;at the national level,it needs to accelerate the establishment of ESG disclosure-related laws and regulations and establish a unified disclosure standard.Based on the ESG report of Lizhu Pharmaceutical,the article hopes to play a role in improving the quality of information disclosure in the pharmaceutical industry.